КАРДИОПРОТЕКТИВНАЯ ИНОТРОПНАЯ ТЕРАПИЯ – ВОЗМОЖНОСТИ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ЛЕВОСИМЕНДАНА В КАРДИОХИРУРГИИ
https://doi.org/10.21292/2078-5658-2016-13-2-70-77
Аннотация
Фармакологическая поддержка циркуляции до сих пор является краеугольным камнем при ведении пациентов с миокардиальной дисфункцией. В статье рассмотрены современные теоретические и практические аспекты использования левосимендана в кардиохирургии как инотропного препарата с уникальным механизмом действия и кардиопротективными свойствами.
Об авторах
В. В. Пасюга
ФГБУ «ФЦССХ Минздрава России», г. Астрахань
Россия
заведующий отделением анестезиологии-реанимации
Россия
заведующий отделением анестезиологии-реанимации
В. В. Ломиворотов
ФГБУ «ННИИ ПК им. акад. Е. Н. Мешалкина» МЗ РФ, г. Новосибирск
Россия
доктор медицинских наук, профессор, заместитель директора по научной работе, руководитель центра анестезиологии и реаниматологии
Россия
доктор медицинских наук, профессор, заместитель директора по научной работе, руководитель центра анестезиологии и реаниматологии
А. А. Еременко
ФГБНУ «РНЦХ им. акад. Б. В. Петровского», г. Москва
Россия
доктор медицинских наук, профессор, заведующий отделением кардиореанимации и интенсивной терапии, заслуженный врач РФ
Россия
доктор медицинских наук, профессор, заведующий отделением кардиореанимации и интенсивной терапии, заслуженный врач РФ
Список литературы
1. Григорьев E. В., Торопова Я. Г., Плотников Г. П. и др. Фармакологическая кардиопротекция при реперфузии изолированного сердца // Анестезиол. и реаниматол. – 2015. – № 2. – C. 12–16.
2. Еременко А. А., Колпаков П. Е., Бабаев М. А. и др. Применение левосимендана у кардиохирургических больных с хронической сердечной недостаточностью // Анестезиол. и реаниматол. – 2010. – № 2. – C. 24–27.
3. Ломиворотов В. В., Еременко А. А., Бобошко В. А. и др. Периоперационное использование левосимендана в кардиохирургии // Патология кровообращения и кардиохирургия. – 2015. – Т. 19, № 2. – С. 113–123.
4. Abraham W., Adams K., Fonarow G. et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medication: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) // J. Am. Coll. Cardiol. – 2005. – Vol. 46. – P. 57–64.
5. Adamopoulos S., Parissis J., Iliodromitis E. et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure // Am. J. Cardiol. – 2006. – Vol. 98. – P. 102–106.
6. Alvarez J., Baluja A., Selas S. et al. A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study // Anaesth. Int. Care. – 2013. – Vol. 41. – P. 719–727.
7. Bassani R. A., Bassani J. W., Bers D. M. et al. Relaxation in ferret ventricular myocytes: role of the sarcolemmal Ca++ATPase // Pflugers Atchiv. – 1995. – Vol. 430. – P. 573–578.
8. Baysal A., Yanartas M., Dogukan M. et al. N. Levosimendan improves renal outcome in cardiac surgery: a randomised trial // J. Cardiothorac. Vasc. Anesth. – 2014. – Vol. 28. – P. 586–594.
9. Bers D. M., Measurment of Calcium transport in heart using modern approaches // New Horizons. – 1996. – Vol. 4. – P. 36–44.
10. Bers D. M. Calcium fluxes involved in control of cardiac myocyte contraction // Circ. Res. – 2000. – Vol. 87. – P. 275–281.
11. Bers D. M. Cardiac excitation-contraction coupling // Nature. – 2001. – Vol. 415. – P. 198–205.
12. Blinks J. R., Endoh M. Modification of myofibrillar responsiveness to Ca2+ as an inotropic mechanism // Circulation. – 1986. – Vol. 73. – Р. III85–III98.
13. Caimmi P. P., Kapetanakis E. I., Beggino C. et al. Management of acute cardiac failure by intracoronary administration of levosimendan // J. Cardiovasc. Pharmacol. TM. – 2011. – Vol. 58. – P. 246–253.
14. Cammarata G. A., Weil M. H., Sun S. et al. Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation // J. Am. Coll. Cardiol. – 2006. – Vol. 47. – P. 1083–1085.
15. Chen Q., Camara A. K., Rhodes S. S. et al. Cardiotonic drugs differentially alter cytosolic [Ca2+] to left ventricular relationships before and after ischemia in isolated guinea pig hearts // Cardiovasc. Res. – 2003. – Vol. 59. – P. 912–925.
16. de Hert S. G., Lorsomradee S., vanden Eede H. et al. A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction // J. Cardiothor. Vasc. Anesthesia. – 2008. – Vol 22, № 5. – P. 699–705.
17. Diaz M. E., Graham H. K., O’Neill S. C. et al. The control of carcoplasmic reticulum Ca2+content in cardiac muscle // Cell. Calcium. – 2005. – Vol. 38. – P. 391–396.
18. Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. Heart J. – 2008. – Vol. 29. – P. 2388–2442.
19. du Toit E. F., Genis A., Opie L. H. et al. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart // Br. J. Pharmacol. – 2008. – Vol. 154. – P. 41–50.
20. Edes I., Kiss E., Kitada Y. et al. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart // Circ Res. – 1995. – Vol. 77. – P. 107–113.
21. Endoh M., Hori M. Acute heart failure: inotropic agents and their clinical uses // Expert. Opin Pharmacother. – 2006. – Vol. 7. – P. 2179–2202.
22. Erdei N., Papp Z., Pollesello P. et al. The levosimendan metabolite OR–1896 elicits vasodilation by activating the K (ATP) and BK(Ca) channels in rat isolated arterioles // Br. J. Pharmacol. – 2006. – Vol. 148. – P. 696–702.
23. Fonarow G. C., Heywood J. T., Heidenreich P. A. et al. Temporal trends in clinical characteristics, treatments and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE) // Am. Heart J. – 2007. – Vol. 153. – P. 1021–1028.
24. Giannakoulas G., Giannoglou G., Vassilikos V. et al. Clinical significance of acute neurohormonal response after levosimendan treatment // Am. J. Cardiol. – 2006. – Vol. 98. – P. 1123–1124.
25. Goetzenich A., Hatam N., Preuss S. et al. The role of hypoxia-inducible factor-1α and vascular endothelial growth factor in late-phase preconditioning with xenon, isoflurane and levosimendan in rat cardiomyocytes // Interact. Cardiovasc. Thorac. Surg. – 2014. – Vol. 18, № 3. – P. 321–328.
26. Greco T., Calabrò M. G., Covello R. D. et al. Bayesian network meta-analysis on the effect of inodilatory agents on mortality // Br. J. Anaesth. – 2015. – Vol. 114, № 5. – P. 746–756.
27. Grossini E., Caimmi P. P., Molinary C. et al. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig // J. Cardiovasc. Pharmacol. – 2006. – Vol. 46. – P. 333–342.
28. Haikala H., Nissinen E., Etemzadeh E. et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation // J. Cardiovasc. Pharmacol. – 1995. – Vol. 25. – P. 794–801.
29. Harrison R. W., Hasselblad V., Mehta R. H. et al. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis // J. Cardiothor. Vascular Anesthesia. – 2013. – Vol. 27, № 6. – P. 1224–1232.
30. Honisch A., Theuring N., Ebner B. et al. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition // Basic. Res. Cardiol. – 2009. – Vol. 105. – P. 155–167.
31. Jamali I. N., Kersten J. R., Pagel P. S. et al. Intracoronary levosimendan enhances contractile function of stunned myocardium // Anesth. Analg. – 1997. – Vol. 85. – P. 23–29.
32. Landoni G., Augoustides J. G., Guarracino F. et al. Mortality reduction in cardiac anesthesia and intensive care: Results of the Firs International Consensus Conference // Acta Anaesthesiol. Scand. – 2011. – Vol. 55. – P. 259–266.
33. Landoni G., Biondi-Zoccai G., Greco M., et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies // Crit. Care Med. – 2012. – Vol. 40. – P. 634–646.
34. Landoni G., Mizzi A., Biondi-Zoccai G. et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials // J. Cardiothorac. Vascular Anesthesia. – 2010. – Vol 24, № 1. – P. 51–57.
35. Levin R., Degrange M., Del Mazo C. et al. Preoperative levosimendan decreases mortality and the development of low cardiac output in high–risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass // Exp. Clin. Cardiol. – 2012. – Vol. 17. – P. 125–130.
36. Lochner A., Colesky F., Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium // Cardiovasc. Drugs Ther. – 2000. – Vol. 14. – P. 271–281.
37. Maharaj R., Metaxa V., Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials // Crit. Care. – 2011. – Vol. 15. – Р. R140.
38. Mebazaa A., Nieminen M. S., Packer M. et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVED Randomized Trial // JAMA. – 2007. – Vol. 297. – P. 1883–1891.
39. Niu Z. Z., Wu S. M., Sun W. Y. et al. Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis // J. Cardiovasc. Pharmacol. – 2014. – Vol. 63. – P. 107–112.
40. Packer M., Carver J. R., Rodeheffer R. J. at al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group // N. Engl. J. Med. – 1991. – Vol. 325. – P. 1468–1475.
41. Papp J. G., Pollesello P., Varro A. F. et al. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs // J. Cardiovasc. Pharmacol. Ther. – 2006. – Vol. 11. – P. 129–135.
42. Papp Z., Edes I., Fruhwald S. et al. Levosimendan: Molecular mechanisms and clinical implications consensus of experts on the mechanisms of action of levosimendan // Int. J. Cardiol. – 2012. – Vol. 159, № 2. – P. 82–87.
43. Parissis J. T., Adamopoulos S., Antoniades C. et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure // Am. J. Cardiol. – 2004. – Vol. 93. – P. 1309–1312.
44. Parissis J. T., Andreadou I., Markantonis S. L. et al. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure // Atherosclerosis. – 2007. – Vol. 195. – Р. e210–е215.
45. Parissis J. T., Karavidas A., Bistola V. et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure // Atherosclerosis. – 2008. – Vol. 197. – P. 278–282.
46. Robertson I. M., Sun Y. B., Li M. X. et al. A structural and functional perspective into the mechanism of Ca++-sensitizers that target the cardiac troponin complex // J. Mol. Cell. Cardiol. – 2010. – Vol. 49, № 6. – P. 1031–1041.
47. Sorsa T., Heikkinen S., Abbott M. B. et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C // J. Biol. Chem. – 2001. – Vol. 276. – P. 9337–9343.
48. Sorsa T., Pollesello P., Rosevear P. R. et al., Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization // Eur. J. Pharmacol. – 2004. – Vol. 486. – P. 1–8.
49. Sponga S., Ivanitskaia E., Potapov E. et al. Preoperative treatment with levosimendan in candidates for mechanical circulatory support // ASAIO J. – 2012. – Vol. 58. – P. 6–11.
50. Szilágyi S., Pollesello P., Levijoki J. et al. The effects of levosimendan and OR– 1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig // Eur. J. Pharmacol. – 2004. – Vol. 486. – P. 67–74.
51. Theiss H. D., Grabmaier U., Kreissl N. et al. Preconditioning with levosimendan before implantation of left ventricular assist devices // Artif. Organs. – 2014. – Vol. 38. – P. 231–234.
52. Toller W., Algotsson L., Guarracino F. et al. Perioperative use of levosimendan: best practice in operative settings // J. Cardiothor. Vascular Anesthesia. – 2013. – Vol. 27, № 2. – P. 361–366.
53. Toller W., Heringlake M., Guarracino F. et al. Preoperative and perioperative use of levosimendan in cardiac surgery European expert opinion // Int. J. Cardiology. – 2015. – Vol. 184. – P. 323–336.
54. Tritapepe L., de Santis V., Vitale D. et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery // Brit. J. Anaesthesia. – 2009. – Vol. 102, № 2. – P. 198–204.
Рецензия
Для цитирования:
Пасюга В.В., Ломиворотов В.В., Еременко А.А. КАРДИОПРОТЕКТИВНАЯ ИНОТРОПНАЯ ТЕРАПИЯ – ВОЗМОЖНОСТИ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ЛЕВОСИМЕНДАНА В КАРДИОХИРУРГИИ. Вестник анестезиологии и реаниматологии. 2016;13(2):70-77. https://doi.org/10.21292/2078-5658-2016-13-2-70-77
For citation:
Pasyuga V.V., Lomivorotov V.V., Eremenko A.A. CARDIAC PROTECTIVE INOTROPIC THERAPY – OPPORTUNITIES AND PROSPECTIVE OF USING LEVOSIMENDAN IN CARDIAC SURGERY. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2016;13(2):70-77. (In Russ.) https://doi.org/10.21292/2078-5658-2016-13-2-70-77
Послать статью по эл. почте 